| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/25/2013 | WO2013057944A1 Novel spiroindoline compound, and medicinal agent comprising same |
| 04/25/2013 | WO2013057724A1 Packaging for alitretinoin |
| 04/25/2013 | WO2013057722A1 New salt and medical use |
| 04/25/2013 | WO2013057711A1 Quinazoline derivatives as pi3k modulators |
| 04/25/2013 | WO2013057675A1 Alkenylglucosinolate detoxifying composition |
| 04/25/2013 | WO2013057650A1 Novel substituted imidazopyrimidines as gpbar1 receptor modulators |
| 04/25/2013 | WO2013057624A1 Use of aminoacetonitrile derivatives against endoparasites |
| 04/25/2013 | WO2013057619A1 Novel phenicol antibacterials |
| 04/25/2013 | WO2013057593A1 Process for the preparation of lersivirine |
| 04/25/2013 | WO2013057592A2 Treatment of sickle cell disease |
| 04/25/2013 | WO2013057580A1 Method for treating capillary hemangiomas |
| 04/25/2013 | WO2013057554A2 Therapeutic combinations of netupitant and palonosetron |
| 04/25/2013 | WO2013057545A1 Acid addition salts of bosentan |
| 04/25/2013 | WO2013057527A2 Compounds for treatment of ishcemic injury |
| 04/25/2013 | WO2013057487A1 Phytocannabinoids for use in the treatment of breast cancer |
| 04/25/2013 | WO2013057485A1 Anti sense oligonucleotides for apob exon- skipping |
| 04/25/2013 | WO2013057469A1 Pharmaceutical antiretroviral compositions |
| 04/25/2013 | WO2013057461A1 Paste comprising non-steroidal anti-inflammatory |
| 04/25/2013 | WO2013057422A1 Anti-diabetic aminosteroid derivatives |
| 04/25/2013 | WO2013057372A1 Novel non-steroidal compounds as androgen receptor modulators |
| 04/25/2013 | WO2013057354A1 Use of melatonin for treating and/or preventing mucositis |
| 04/25/2013 | WO2013057322A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| 04/25/2013 | WO2013057287A1 Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| 04/25/2013 | WO2013057284A1 Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof |
| 04/25/2013 | WO2013057253A1 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| 04/25/2013 | WO2013057251A2 Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| 04/25/2013 | WO2013057222A2 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones |
| 04/25/2013 | WO2013057212A1 Dosage regimen for an s1p receptor modulator or agonist |
| 04/25/2013 | WO2013057208A1 Compositions and methods for reducing the proliferation and viability of microbial agents |
| 04/25/2013 | WO2013057205A1 Diazabicyclo- and diazaspiro-alkane derivatives as phosphodiesterase-5 inhibitors |
| 04/25/2013 | WO2013057197A1 Process for the formylation of cefamandole |
| 04/25/2013 | WO2013057196A1 Process for the preparation of cefamandole nafate |
| 04/25/2013 | WO2013057183A1 Compositions for controlling vascularization in ophthalmological and dermatological diseases |
| 04/25/2013 | WO2013057148A1 ACID ADDITION SALTS OF 5α-HYDROXY-6β-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3β-OL |
| 04/25/2013 | WO2013057124A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone |
| 04/25/2013 | WO2013057101A1 Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors |
| 04/25/2013 | WO2013057072A1 Composition for use in the promotion of magnesium absorption and/or magnesium retention |
| 04/25/2013 | WO2013057063A1 Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease |
| 04/25/2013 | WO2013057062A1 Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery |
| 04/25/2013 | WO2013057061A1 Composition for use in increasing insulin sensitivity and/or reducing insulin resistance |
| 04/25/2013 | WO2013057049A1 Composition for use in brain growth and/or cognitive and/or psychomotor development |
| 04/25/2013 | WO2013057013A2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| 04/25/2013 | WO2013056992A1 Improvements in or relating to organic compounds |
| 04/25/2013 | WO2013056915A1 Microbiocidal pyrazole derivatives |
| 04/25/2013 | WO2013056852A1 Glucagon binding nucleic acids |
| 04/25/2013 | WO2013056730A1 Systemic use of compounds in humans that kill free-living blood-feeding ectoparasites |
| 04/25/2013 | WO2013056684A2 Thiazole derivative as dhodh inhibitor and use thereof |
| 04/25/2013 | WO2013056679A1 Novel heteroaryl-amino derivatives |
| 04/25/2013 | WO2013056547A1 Synthesis of a group of hydantoin derivatives and use thereof |
| 04/25/2013 | WO2013056510A1 Use for deoxynucleoside/nucleoside combination in preparation of tumor medicament |
| 04/25/2013 | WO2013056501A1 Compositions and methods for quantitative detection of microorganisms and cells |
| 04/25/2013 | WO2013056327A1 Cleaning solution for contact lenses |
| 04/25/2013 | WO2013056326A1 Controlled release pharmaceutical composition containing naltrexone and topiramate |
| 04/25/2013 | WO2013056309A1 Novel plant defensins and use in the treatment of proliferative diseases |
| 04/25/2013 | WO2013056298A1 Pharmaceutical compositions of resveratrol |
| 04/25/2013 | WO2013034927A8 Compositions of lopinavir and ritonavir |
| 04/25/2013 | WO2013033004A3 Metalloenzyme inhibitor compounds |
| 04/25/2013 | WO2013032643A3 Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| 04/25/2013 | WO2013032184A3 Composition comprising pyrazino-triazine derivatives |
| 04/25/2013 | WO2013032158A3 Method for inducing stem-cells to differentiate into muscle cells |
| 04/25/2013 | WO2013030218A4 Selective and reversible inhibitors of ubiquitin specific protease 7 |
| 04/25/2013 | WO2013027986A3 Method of screening for chaperonin modulator |
| 04/25/2013 | WO2013025882A3 Tricyclic compounds as anticancer agents |
| 04/25/2013 | WO2013025442A3 Concentrated felbamate formulations for parenteral administration |
| 04/25/2013 | WO2013022550A3 Small molecule inhibitors of ebola and lassa fever viruses |
| 04/25/2013 | WO2013022280A3 N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| 04/25/2013 | WO2013022279A3 N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| 04/25/2013 | WO2013022278A3 N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| 04/25/2013 | WO2013019658A3 Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| 04/25/2013 | WO2013019093A3 Novel aniline derivatives and use thereof |
| 04/25/2013 | WO2013019091A3 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| 04/25/2013 | WO2013016452A3 Cancer treatment using bmp inhibitor |
| 04/25/2013 | WO2013013038A3 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 04/25/2013 | WO2013012485A3 Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 04/25/2013 | WO2013009844A3 C-3 substituted bicyclooctane based hiv protease inhibitors |
| 04/25/2013 | WO2013008240A3 Liposomes co-encapsulating a bisphosphonate and an amphipathic agent |
| 04/25/2013 | WO2013006864A3 Treating cancer with hsp90 inhibitory compounds |
| 04/25/2013 | WO2013006335A3 Methods and compositions useful for treating fitzpatrick type iv, v or vi skin |
| 04/25/2013 | WO2013005168A3 Cannabinoid receptor modulators |
| 04/25/2013 | WO2013001372A3 Methods and compositions for inhibition of activation of regulatory t cells |
| 04/25/2013 | WO2012177603A3 Metalloenzyme inhibitor compounds |
| 04/25/2013 | WO2012174488A3 Agents and methods for treating ischemic and other diseases |
| 04/25/2013 | WO2012174487A3 Bromodomain inhibitors and uses thereof |
| 04/25/2013 | WO2012174164A3 Agonists of gpr131 and uses thereof |
| 04/25/2013 | WO2012170951A3 Compounds that modulate intracellular calcium |
| 04/25/2013 | WO2012166706A3 Supramolecular nanofibers and hydrogels based on oligopeptides functionalized with nucleobases |
| 04/25/2013 | WO2012162629A3 Popcorn shape gold nanoparticle for targeted diagnosis, photothermal treatment and in-situ monitoring therapy response for cancer and multiple drug resistance bacteria |
| 04/25/2013 | WO2012162412A3 Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use |
| 04/25/2013 | WO2012161559A3 A use of a composition comprising of acylated steryl glucoside in the manufacture of a product |
| 04/25/2013 | WO2012139039A3 Bisphenol compounds and methods for their use |
| 04/25/2013 | WO2012122340A8 Soluble guanylate cyclase activators |
| 04/25/2013 | WO2012037928A3 Compounds for the diagnosis of neurodegenerative disorders on the olfactory epithelium |
| 04/25/2013 | WO2011160042A3 Prpk-tprkb modulators and uses thereof |
| 04/25/2013 | WO2011061761A3 Pharmaceutical composition for parenteral use comprising mycophenolate mofetil |
| 04/25/2013 | WO2011024049A9 Method for producing proanthocyanidin polymer compositions for pharmaceutical formulations |
| 04/25/2013 | WO2010084115A3 Antiviral agents |
| 04/25/2013 | US20130102977 Ophthalmic composition |
| 04/25/2013 | US20130102796 Agent for promoting osteoblast differentiation, pharmaceutical composition for promoting bone formation, and food for special dietary use containing auraptene analog as active ingredient |
| 04/25/2013 | US20130102769 Interfering rna molecules |
| 04/25/2013 | US20130102683 Melt-granulated fingolimod |